SGLT2-I was highlighted as a useful supplement in patients with HF who are already receiving beta-blockers, angiotensin receptor, and neprilysin inhibitors, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, as well as an aldosterone receptor antagonist, regardless of the presence of diabetes mellitus, in the 2021 update to the "2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment" [35]. The gene discussed is ACE; the disease is heart failure.